Your $199/Month ‘Ozempic Alternative’ May Be About to Disappear—Because of a 503B Loophole Most Patients (and Telehealth Ads) Don’t Understand
The cheap GLP‑1 subscription boom was built on FDA shortage status—and a temporary enforcement window that began closing in 2025. Many ads didn’t keep up with the dates, the rules, or what “503B” actually allows.
By TheMurrow Editorial
May 8, 2026
Key Points
- 1Recognize what you’re buying: many “$199/month Ozempic alternatives” are compounded semaglutide/tirzepatide—not FDA-approved Ozempic, Wegovy, Mounjaro, or Zepbound.
- 2Track the shortage switch: FDA says semaglutide injection shortage resolved Feb 21, 2025, with enforcement discretion ending April 22 (503A) and May 22 (503B).
- 3Challenge the “503B” pitch: FDA-registered facilities aren’t selling FDA-approved drugs, and bulk compounding narrows when substances aren’t on the 503B bulks list.
A year ago, the ad was everywhere—and the fine print wasn’t
A year ago, it was hard to scroll Instagram without seeing it: a sleek telehealth brand promising a “$199/month Ozempic alternative,” shipped to your door, no waiting room, no awkward conversation. The ads spoke the language of frictionless modern medicine—subscription pricing, quick consults, discreet delivery.
Many readers assumed the drug in the box was Ozempic® or Wegovy® (Novo Nordisk) or Mounjaro®/Zepbound® (Eli Lilly). In most cases, it wasn’t. What many companies were actually selling was a compounded injectable labeled “semaglutide” or “tirzepatide.”
That difference isn’t semantic. It sits at the center of a shifting legal and regulatory story—one that changed sharply in 2025 when federal shortage designations ended and the FDA’s temporary “enforcement discretion” windows began to close.
Many readers assumed the drug in the box was Ozempic® or Wegovy® (Novo Nordisk) or Mounjaro®/Zepbound® (Eli Lilly). In most cases, it wasn’t. What many companies were actually selling was a compounded injectable labeled “semaglutide” or “tirzepatide.”
That difference isn’t semantic. It sits at the center of a shifting legal and regulatory story—one that changed sharply in 2025 when federal shortage designations ended and the FDA’s temporary “enforcement discretion” windows began to close.
“The price is the hook. The fine print is the story.”
— — TheMurrow Editorial
What follows is a plain-English guide to how the “$199/month” GLP‑1 ecosystem grew, what the law actually allows, and why the rules tightened—often faster than the marketing did.
The $199/month GLP‑1 boom: what patients were really buying
The rise of subscription-priced GLP‑1 shots wasn’t an accident. It was a market response to scarcity. During the national GLP‑1 shortages—spanning 2022 through early 2025 for semaglutide injections and 2024 for tirzepatide injections—telehealth companies and compounding pharmacies became a de facto access valve.
Many offers used familiar pricing psychology: a teaser rate around $99–$199 per month, auto-renewal, and a message that sounded like a consumer upgrade rather than a clinical decision. The drug itself was typically a compounded preparation labeled “semaglutide” or “tirzepatide,” not the branded products manufactured by Novo Nordisk or Eli Lilly.
That matters because compounded drugs do not travel through the same approval pathway as FDA-approved brand drugs. Compounding can be legal and clinically appropriate in narrow circumstances. It can also fall outside the law’s safe harbors—especially when the compounded product is, functionally, a copy of an FDA-approved drug.
Many offers used familiar pricing psychology: a teaser rate around $99–$199 per month, auto-renewal, and a message that sounded like a consumer upgrade rather than a clinical decision. The drug itself was typically a compounded preparation labeled “semaglutide” or “tirzepatide,” not the branded products manufactured by Novo Nordisk or Eli Lilly.
That matters because compounded drugs do not travel through the same approval pathway as FDA-approved brand drugs. Compounding can be legal and clinically appropriate in narrow circumstances. It can also fall outside the law’s safe harbors—especially when the compounded product is, functionally, a copy of an FDA-approved drug.
$99–$199/month
Common teaser pricing used in subscription-style telehealth offers for compounded GLP‑1 injections during the shortage era.
What advertising often left out
Many patients reasonably assumed: “If a clinician prescribed it, it must be allowed.” Federal law doesn’t work that way. Compounding legality hinges on specific statutory pathways—chiefly FD&C Act §§503A and 503B—and on whether the FDA lists the drug as being in shortage.
A prescription is necessary in some scenarios, but it isn’t the only gatekeeper. The framework asks a tougher question: Is this compounding addressing a genuine clinical need, or mass-producing a substitute for a commercially available drug?
A prescription is necessary in some scenarios, but it isn’t the only gatekeeper. The framework asks a tougher question: Is this compounding addressing a genuine clinical need, or mass-producing a substitute for a commercially available drug?
“A doctor’s signature doesn’t automatically turn a copy into a compliant compound.”
— — TheMurrow Editorial
Compounding, in plain English: the difference between 503A and 503B
The U.S. compounding system has two main lanes. The names—503A and 503B—sound like tax forms, but the distinction is crucial for anyone deciding whether to trust a subscription GLP‑1 offer.
The FDA lays out these contours in its GLP‑1 compounding statements and policy clarifications. (Readers can start with the FDA page titled “FDA clarifies policies as compounders’ national GLP‑1 supply begins to stabilize.”)
The FDA lays out these contours in its GLP‑1 compounding statements and policy clarifications. (Readers can start with the FDA page titled “FDA clarifies policies as compounders’ national GLP‑1 supply begins to stabilize.”)
503A: patient-specific compounding
Section 503A generally applies to state-licensed pharmacies (and physicians) that compound a medication for an individual patient after receiving a patient-specific prescription.
That sounds like the idealized version of compounding: a pharmacist customizes a medication because a patient needs something different. The law, however, draws a bright line around copying.
503A compounding is limited when a compounded drug is “essentially a copy” of a commercially available FDA-approved drug—unless the prescriber documents a clinically significant difference for that patient. The research example is straightforward: an allergy to an excipient or an ingredient issue that requires a change.
In other words, “I want the cheaper version” is not the clinical justification the statute contemplates.
That sounds like the idealized version of compounding: a pharmacist customizes a medication because a patient needs something different. The law, however, draws a bright line around copying.
503A compounding is limited when a compounded drug is “essentially a copy” of a commercially available FDA-approved drug—unless the prescriber documents a clinically significant difference for that patient. The research example is straightforward: an allergy to an excipient or an ingredient issue that requires a change.
In other words, “I want the cheaper version” is not the clinical justification the statute contemplates.
503B: outsourcing facilities and batch compounding
Section 503B covers FDA-registered outsourcing facilities. These entities can compound in larger batches, generally supplying healthcare facilities and office use.
The existence of “FDA-registered” in the 503B description has been a gift to marketers. It can sound like the product itself is FDA-approved. It isn’t. 503B status refers to the facility category and oversight structure—not to a branded stamp of approval on each compounded drug.
And 503B comes with a constraint that matters immensely for semaglutide and tirzepatide: outsourcing facilities generally may compound from bulk drug substances only if:
- the substance is on the 503B bulks list (substances the FDA recognizes as having clinical need), or
- the drug is on the FDA drug shortage list at the time of compounding/dispensing.
According to the FDA’s GLP‑1 compounding statements, semaglutide and tirzepatide are not on the 503B bulks list. Once shortage status ends, the “batch compounding from bulk” lane narrows dramatically.
The existence of “FDA-registered” in the 503B description has been a gift to marketers. It can sound like the product itself is FDA-approved. It isn’t. 503B status refers to the facility category and oversight structure—not to a branded stamp of approval on each compounded drug.
And 503B comes with a constraint that matters immensely for semaglutide and tirzepatide: outsourcing facilities generally may compound from bulk drug substances only if:
- the substance is on the 503B bulks list (substances the FDA recognizes as having clinical need), or
- the drug is on the FDA drug shortage list at the time of compounding/dispensing.
According to the FDA’s GLP‑1 compounding statements, semaglutide and tirzepatide are not on the 503B bulks list. Once shortage status ends, the “batch compounding from bulk” lane narrows dramatically.
“503B is not a permission slip to manufacture a ‘generic Ozempic’ on demand.”
— — TheMurrow Editorial
The shortage switch: how one FDA status powered a national subscription market
For many readers, the key turning point is a single administrative fact: whether the FDA considers a drug to be in shortage. That designation changes what compounding can look like in practice.
The shortage era didn’t just increase demand. It widened the space in which compounded copies could proliferate.
The shortage era didn’t just increase demand. It widened the space in which compounded copies could proliferate.
Semaglutide: shortage resolved, then a countdown
The FDA states it determined the shortage of semaglutide injection products was resolved on February 21, 2025.
That date is one of the most important numbers consumers almost never saw in ads. It marked the beginning of the end of the broad justification for scaling compounded semaglutide as a routine substitute.
The FDA also announced time-limited enforcement discretion—a transitional period during which it did not intend to take action against certain compounders making “essentially a copy” products:
- 503A: through April 22, 2025 (60 days after the resolution date)
- 503B: through May 22, 2025 (90 days after the resolution date)
Those are not casual grace periods. They are explicit windows with end dates, published by the FDA.
That date is one of the most important numbers consumers almost never saw in ads. It marked the beginning of the end of the broad justification for scaling compounded semaglutide as a routine substitute.
The FDA also announced time-limited enforcement discretion—a transitional period during which it did not intend to take action against certain compounders making “essentially a copy” products:
- 503A: through April 22, 2025 (60 days after the resolution date)
- 503B: through May 22, 2025 (90 days after the resolution date)
Those are not casual grace periods. They are explicit windows with end dates, published by the FDA.
February 21, 2025
The FDA date stating semaglutide injection products’ shortage was resolved—triggering a countdown for enforcement discretion windows.
April 22, 2025
The FDA’s stated end date (60 days post-resolution) for 503A enforcement discretion related to certain semaglutide “essentially a copy” compounding.
May 22, 2025
The FDA’s stated end date (90 days post-resolution) for 503B enforcement discretion related to certain semaglutide “essentially a copy” compounding.
Tirzepatide: a similar story, with its own timeline
The FDA’s GLP‑1 compounding page also describes a related enforcement-discretion timeline for tirzepatide following litigation efforts. The research notes that (for 503B) non-enforcement tied to shortage status extended through March 19, 2025.
The practical effect is simple: the business model that flourished in a shortage—monthly subscriptions, broad marketing, scaled fulfillment—became harder to justify once the shortage “switch” flipped off and the transition windows ended.
The practical effect is simple: the business model that flourished in a shortage—monthly subscriptions, broad marketing, scaled fulfillment—became harder to justify once the shortage “switch” flipped off and the transition windows ended.
The “503B loophole” claim: what’s real, what’s misleading
Patients hear versions of the same reassurance: “It’s made at a 503B outsourcing facility, so it’s legal.” Sometimes the line is subtler: “FDA-registered facility.” The implication is that 503B status functions like a back door to mass-produce semaglutide or tirzepatide indefinitely.
The FDA’s own framing is less romantic and far more conditional.
The FDA’s own framing is less romantic and far more conditional.
What the FDA actually says—without the marketing gloss
The FDA has emphasized that 503B outsourcing facilities are restricted from compounding using bulk substances unless the substance is on the 503B bulks list or the drug is on the shortage list.
In the FDA’s GLP‑1 compounding statements, the agency notes that semaglutide and tirzepatide do not currently appear on either—not on the bulks list, and, after the shortage determinations, not on the shortage list.
That means the commonly advertised idea of a permanent “503B workaround” doesn’t match the policy logic the FDA describes.
In the FDA’s GLP‑1 compounding statements, the agency notes that semaglutide and tirzepatide do not currently appear on either—not on the bulks list, and, after the shortage determinations, not on the shortage list.
That means the commonly advertised idea of a permanent “503B workaround” doesn’t match the policy logic the FDA describes.
A fair counterpoint: why some clinicians and patients supported compounding during shortages
During true shortages, compounding filled a real gap. Patients with diabetes or obesity-related conditions weren’t imagining the problem; access constraints were widespread.
From that perspective, compounders and telehealth prescribers can argue they helped patients continue care when branded supply couldn’t meet demand. For many individuals, the alternative to compounding wasn’t the brand drug—it was no GLP‑1 therapy at all.
That argument is strongest when shortages are active and weakest when supply stabilizes. The law is written to reflect that difference.
From that perspective, compounders and telehealth prescribers can argue they helped patients continue care when branded supply couldn’t meet demand. For many individuals, the alternative to compounding wasn’t the brand drug—it was no GLP‑1 therapy at all.
That argument is strongest when shortages are active and weakest when supply stabilizes. The law is written to reflect that difference.
How subscription telehealth collided with patient-specific law
The subscription model—flat monthly prices, standardized dosing, and “one-to-many” marketing—fits neatly into consumer tech. It fits awkwardly into a legal regime that, in its 503A form, is built around individual patients and individualized need.
Where the friction appears
503A compounding is centered on patient-specific prescriptions and limits “essentially a copy” compounding unless there is a documented clinically significant difference.
A mass-market GLP‑1 offer, by design, tends to look like the opposite:
- one product offered to many patients,
- predictable titration schedules,
- pricing and fulfillment that resemble a membership club.
None of that proves illegality by itself. But it raises the central question regulators care about: Are compounded semaglutide or tirzepatide injections being used as customized therapies—or as scalable substitutes for commercial products now that shortages are resolved?
A mass-market GLP‑1 offer, by design, tends to look like the opposite:
- one product offered to many patients,
- predictable titration schedules,
- pricing and fulfillment that resemble a membership club.
None of that proves illegality by itself. But it raises the central question regulators care about: Are compounded semaglutide or tirzepatide injections being used as customized therapies—or as scalable substitutes for commercial products now that shortages are resolved?
Expert voice: what the FDA has put in writing
The most relevant “expert” in this specific dispute is the regulator itself. In its public GLP‑1 compounding communications, the FDA clarifies that compounders’ ability to make products that are “essentially a copy” is closely tied to shortage status and to the statutory restrictions in 503A/503B. The agency also provides the explicit dates for semaglutide’s shortage resolution (February 21, 2025) and the end of the enforcement discretion windows (April 22, 2025 for 503A; May 22, 2025 for 503B).
That written guidance matters because it undercuts the idea that compounding policy is a vague gray zone. The FDA has been unusually direct, including timelines.
That written guidance matters because it undercuts the idea that compounding policy is a vague gray zone. The FDA has been unusually direct, including timelines.
Two real-world case studies: how the same ad can mean different things
Readers deserve concrete scenarios. The same phrase—“compounded semaglutide”—can describe very different compliance realities depending on timing, pharmacy type, and rationale.
Case study 1: The shortage-era subscriber (late 2024)
A patient sees a $199/month telehealth offer for compounded semaglutide in late 2024. Branded supply is difficult to obtain. The compounded product is positioned as a pragmatic substitute during scarcity.
In that context, the shortage designation functioned as a key justification for scaled compounding. Consumers could still ask hard questions about sourcing and oversight, but the policy environment was meaningfully different. Shortage status made the “access valve” argument more plausible, especially for 503B facilities whose ability to compound from bulk is tied to the shortage list.
Key facts readers can anchor to:
- Semaglutide injection shortages spanned 2022 through early 2025 (per the research summary).
- The shortage wasn’t resolved until February 21, 2025 (FDA).
In that context, the shortage designation functioned as a key justification for scaled compounding. Consumers could still ask hard questions about sourcing and oversight, but the policy environment was meaningfully different. Shortage status made the “access valve” argument more plausible, especially for 503B facilities whose ability to compound from bulk is tied to the shortage list.
Key facts readers can anchor to:
- Semaglutide injection shortages spanned 2022 through early 2025 (per the research summary).
- The shortage wasn’t resolved until February 21, 2025 (FDA).
Case study 2: The post-window subscriber (summer 2025)
Now replay the same subscription offer in summer 2025. Semaglutide injection shortage has been resolved since February 21, 2025. The FDA’s transition periods ended on April 22, 2025 (503A) and May 22, 2025 (503B).
A continued “generic Ozempic” style subscription pitch may still circulate online, but the legal scaffolding that made mass compounding easier has been removed.
In this scenario, consumers should interpret the same marketing language differently—not because the words changed, but because the regulatory context did.
A continued “generic Ozempic” style subscription pitch may still circulate online, but the legal scaffolding that made mass compounding easier has been removed.
In this scenario, consumers should interpret the same marketing language differently—not because the words changed, but because the regulatory context did.
What readers should do now: practical checks before you inject anything
Readers shouldn’t have to become pharmacists to protect themselves. Still, the post-2025 environment makes a few basic questions worth asking—especially when a company’s marketing leans hard on price and convenience.
A short checklist you can actually use
Before signing up for a compounded GLP‑1 subscription, ask:
Before you sign up, ask these questions
- ✓Which compounding pathway applies? Is it a 503A pharmacy filling a patient-specific prescription, or a 503B outsourcing facility?
- ✓Is the product essentially a copy of an FDA-approved drug? If yes, what is the clinically significant difference documented for you (not for “patients in general”)?
- ✓What is the current shortage status? For semaglutide injections, the FDA says the shortage was resolved February 21, 2025. For tirzepatide, the FDA page describes enforcement discretion tied to shortage status through March 19, 2025 for 503B in the timeline cited in the research.
- ✓What dates matter for enforcement discretion? Semaglutide: 60 days for 503A to April 22, 2025; 90 days for 503B to May 22, 2025.
- ✓Does the company’s advertising acknowledge these constraints? If the pitch sounds timeless—“always available, always $199”—ask why the regulatory story would not affect supply.
These questions won’t answer everything. They will, however, force transparency in a market that often trades on consumer ambiguity.
Key Insight
If a pitch sounds timeless—“always available, always $199”—ask what changed after shortages ended and why the offer wouldn’t change too.
A market built on scarcity is learning to live without it
The compounded GLP‑1 boom did not emerge because patients were gullible. It emerged because the healthcare system produced a rare combination: blockbuster demand, constrained branded supply, and a compounding framework designed to handle exceptions.
When shortages were active, compounding served as a bridge for many patients. Once the FDA determined that semaglutide injection shortages were resolved on February 21, 2025, the bridge was supposed to narrow again—back toward individualized, clinically justified compounding rather than scaled substitution.
The most uncomfortable truth is also the simplest: consumer marketing moves faster than healthcare law. Telehealth brands can keep buying ads long after the shortage switch flips. Patients can keep assuming a prescription equals compliance. Meanwhile, the rules sit in plain sight—written in statute, reiterated by the FDA, and punctuated by dates: March 19, 2025; April 22, 2025; May 22, 2025.
The next phase of GLP‑1 access will be shaped less by Instagram pricing and more by regulatory gravity. Readers don’t need to panic. They do need to ask better questions than the ads invite.
When shortages were active, compounding served as a bridge for many patients. Once the FDA determined that semaglutide injection shortages were resolved on February 21, 2025, the bridge was supposed to narrow again—back toward individualized, clinically justified compounding rather than scaled substitution.
The most uncomfortable truth is also the simplest: consumer marketing moves faster than healthcare law. Telehealth brands can keep buying ads long after the shortage switch flips. Patients can keep assuming a prescription equals compliance. Meanwhile, the rules sit in plain sight—written in statute, reiterated by the FDA, and punctuated by dates: March 19, 2025; April 22, 2025; May 22, 2025.
The next phase of GLP‑1 access will be shaped less by Instagram pricing and more by regulatory gravity. Readers don’t need to panic. They do need to ask better questions than the ads invite.
Editor’s Note
This article focuses on legality and regulatory posture (503A/503B, shortage status, and enforcement discretion dates), not individual medical advice.
T
About the Author
TheMurrow Editorial is a writer for TheMurrow covering lifestyle.
Frequently Asked Questions
Is a “$199/month Ozempic alternative” actually Ozempic or Wegovy?
Usually not. Many such offers advertise compounded injections labeled “semaglutide” rather than the FDA-approved branded products Ozempic®/Wegovy® (Novo Nordisk). The distinction matters because compounded drugs operate under different legal pathways than FDA-approved drugs, and compounding rules tightened after the FDA declared semaglutide injection shortages resolved.
What does “503A” mean, and why should I care?
503A generally refers to traditional compounding by state-licensed pharmacies (and physicians) for an individual patient with a patient-specific prescription. 503A compounding is limited when the product is “essentially a copy” of a commercially available FDA-approved drug—unless a prescriber documents a clinically significant difference for that patient.
What does “503B outsourcing facility” mean? Is the drug FDA-approved?
A 503B outsourcing facility is FDA-registered and can compound in larger batches, often for healthcare facilities. Registration is not the same as FDA approval of the compounded drug. 503B facilities also face strict limits: they generally may compound from bulk substances only if the substance is on the 503B bulks list or the drug is on the FDA shortage list.
When did the FDA say semaglutide injection shortages ended?
The FDA states it determined the shortage of semaglutide injection products was resolved on February 21, 2025. The agency also announced time-limited enforcement discretion periods related to compounding “essentially a copy” products: through April 22, 2025 for 503A and May 22, 2025 for 503B.
Can pharmacies keep compounding semaglutide or tirzepatide now that shortages are resolved?
The FDA’s GLP‑1 compounding communications indicate that broad “copy” compounding becomes much harder to justify once shortage status ends and enforcement discretion windows close. For 503B facilities in particular, the FDA notes semaglutide and tirzepatide are not on the 503B bulks list, and compounding from bulk is closely tied to shortage-list status.
What questions should I ask a telehealth company offering compounded GLP‑1s?
Ask which pathway applies (503A vs 503B), whether the product is essentially a copy, and what clinically significant difference is documented for you if it is. Ask how the company’s offering relates to the FDA’s shortage determinations and dates—especially February 21, 2025 for semaglutide injections and the end of the semaglutide enforcement discretion windows (April 22, 2025 for 503A; May 22, 2025 for 503B).
